Purple biotech reports additional positive interim data from its randomized phase 2 study with its lead oncology therapeutic candidate cm24

Rehovot, israel, sept. 18, 2024 (globe newswire) -- purple biotech ltd. ("purple biotech" or "the company") (nasdaq/tase: ppbt), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today reported new positive biomarker findings for its lead oncology therapeutic candidate cm24. these data were presented yesterday at the american association for cancer research® (aacr) special conference on advances in pancreatic cancer research currently ongoing in boston, in a poster titled, “exploratory biomarker evaluation of the randomized phase 2 cohort of cm24 in combination with nivolumab and chemotherapy in advanced/metastatic pancreatic cancer”.
PPBT Ratings Summary
PPBT Quant Ranking